An efficient micropropagation protocol for large scale production of hazelnut plants is required for consistent supply of elite germplasm to support the growing industry in Ontario. The main focus of current research was to develop a bioreactor based micropropagation protocol for hazelnut multiplication. An integrated approach was developed to increase the multiplication rate by optimizing the nutrient medium supplements and culture technology using a temporary immersion bioreactor system (TIS). As compared to conventional semi-solid and liquid based culture system, the Liquid LabTM temporary immersion bioreactor system (LIS) showed a significant enhancement in the number of shoots (3.3 shoots/explant), shoot height, leaf area and chlorophyll content in micropropagated plantlets. Antioxidant supplements such as ascorbic acid and melatonin along with iron (460 µM FeEDDHA) significantly increased the shoot proliferation (5.5 shoots/explant). However, a much higher shoot proliferation (10.9 shoots/explant) was observed with the addition of aspirin (10 µM) in the presence of BA (17.6 µM). Among several hazelnut cultivars, HF-16 had the highest multiplication rate followed by Geneva and Epsilon. Medium supplemented with 10 µM IBA was the best for rooting of microshoots of HF-16 and the plantlets acclimatized in the green house with 80% survival rate. / Ontario Ministry of Agriculture and Food and Rural Affairs

<p>In our first study, we explored the barriers to complying with iron supplement recommendations using focus groups. We recruited adults, ages 18-75 years, who have had bariatric surgery at least two months previously to participate in one of four 90-minute focus groups. Participants filled out a survey asking for information on demographics and supplement use, and a facilitator asked a set of pre-determined questions to each group. Responses were written, recorded, transcribed using TranscribeMe (San Francisco CA), and analyzed using NVivo (QSR International Pty Ltd, Doncaster, Victoria). The focus groups contained nineteen participants, five of which had sleeve gastrectomy (SG) and fourteen had Roux-en-Y gastric bypass (RYGB). The average age of the participants was 49.3 ± 9.4 years, and they had undergone surgery 3.9 ± 3.6 years previously. The key factors that influenced participants’ adherence to supplement guidelines were cost, tolerability, and palatability of the supplement, level of knowledge and support from healthcare providers, and convenience of the supplementation regime.</p> <p>The second study was a prospective observational study to determine the bioavailability of ASP compared to FS. Iron deficient RYGB patients ages 18-65 years, who had surgery at least 6 months previously, participated in 8-hour iron absorption tests. Participants received a low-iron breakfast with 65 mg ASP (N=7) or FS (N=3). We assessed serum iron every 30 minutes for 8 hours following the supplementation using a colorimetric assay (South Bend Medical Foundation, South Bend, IN). In participants administered FS, serum iron increased 96.0 ± 27.2 µg/dL compared to baseline, whereas with ASP, serum iron increased 5.8 ± 4.7 µg/dL compared to baseline (<i>P</i> = 0.02). These data indicate that ASP is not as bioavailable as FS in RYGB patients.</p>

Tillgängligheten av blod kan vara livsavgörande för många personer, därför är blodgivning en viktig del av vården. För blodgivare kan en regelbunden blodgivning påverka kroppens järndepåer vilket på sikt kan leda till en järnbrist. Syftet med denna studie var att kartlägga blodgivares järndepåer i Region Jönköpings län genom att (i) utvärdera antalet och andelen nyanmälningar som ej uppfyllt godkänd S-ferritinnivå för blodgivning, (ii) jämföra nivåerna av S-ferritin vid nyregistrering och vid upprepad blodgivning, (iii) utvärdera intag av järnprofylax hos blodgivare, (iv) jämföra antalet, andelen samt orsaken till kontrollprovtagningar före och efter S-ferritin infördes som provtagningsrutin. Data insamlades och erhölls från Blodcentralen, Jönköping, Sverige, och analyserades statistiskt. Resultatet visade att fler kvinnor än män ej blev godkända som blodgivare på grund av S-ferritin &lt;22 µg/L. Genom att sänka S-ferritinnivån kan fler kvinnor godkännas för blodgivning. Vidare visade studien att upprepad blodgivning leder till minskade järndepåer. Grupperna som erbjudits järnprofylax hade stabilare S-ferritin över tid vilket antyder att alla blodgivare skulle gynnas av järnprofylax, men vidare studier krävs. Majoriteten av blodgivare med S-ferritin ≤100 µg/L intar erbjudna järntabletter vilket visade att blodgivarna möjliggjorde fortsatt blodgivning. Slutligen visade studien att sedan S-ferritin infördes som provtagningsrutin 2017 har kontrollprovtagningar på grund av lågt B-Hb minskat, vilket visar att risken för att utveckla en järnbrist på grund av upprepad blodgivning har minskat i Region Jönköpings län. / The availability of blood could be crucial for many people; blood donation is, therefore, a vital part of healthcare. Continuous blood donation could affect the blood donors’ iron depots which could lead to an iron deficiency. The aim of the present study was to evaluate and highlight iron depots amongst blood donors in Jönköping County by (i) evaluating the number and proportion of new applicants which did not meet the approved S-ferritin levels for blood donation, (ii) compare the levels of S-ferritin in new registrations and repeated blood donations, (iii) evaluate intake of iron supplements amongst blood donors, (iv) compare the number, proportion and cause for control sampling before and after S-ferritin was introduced as a sampling routine. Data was collected from the Department of Transfusion Medicine, Jönköping, Sweden, and analysed statistically.The result showed that more women than men were not approved for blood donation because of S-ferritin &lt;22 µg/L. By lowering S-ferritin, additional women will be approved for blood donation. Further, the study showed that continuous blood donation leads to decreased iron depots. Groups that were offered iron supplements showed more stable S-ferritin levels over time which implied that all blood donors would benefit from iron supplements, but further studies are required. The majority of the blood donors with S-ferritin ≤100 µg/L were taking their offered iron supplements which showed that the blood donors enabled future blood donations. Lastly, since S-ferritin was introduced as a sampling routine in 2017 the amount of control samplings due to low B-Hb has decreased. This shows that the risk to develop an iron deficiency due to continuous blood donation has decreased in Jönköping County.